The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×8•Originally published 18 April 2026•Updated 20 April 2026•

1 min read

White House Executive Order to Accelerate Psychedelic Research Boosts Biotech Sector

Key Facts

1The White House issued an Executive Order aimed at accelerating research and access to treatments for serious mental illness using FDA-approved psychedelics.

about 1 month ago

Version History

Version 8about 1 month ago

What changed: Added Biomind Labs (BMND) as an additional entity impacted by the federal order and included their statement of support for the new policy.

Version 7about 1 month ago

What changed: Updated the story to include the significant market response, specifically the 28.1% surge in Atai Life Sciences shares and broad buying momentum across the sector.

Version 6about 1 month ago

What changed: Added Numinus Wellness as a key beneficiary and clarified the scope of the Executive Order to include specific substances like MDMA, LSD, and ibogaine.

Version 5about 1 month ago

What changed: Added details regarding Compass Pathways' COMP360 candidate and clarified its financial status as a pre-revenue pipeline-stage biotech.

Version 4about 1 month ago

Version 3about 1 month ago

What changed: The story was updated with specific regulatory and financial details, including a $50 million funding commitment, DOJ rescheduling instructions, and analyst commentary from RBC.

Version 2about 1 month ago

What changed: Updated the story to include the specific signing date (April 18), the formal title of the Executive Order, the addition of Solvonis Therapeutics to the supporting entities, and the specific medical conditions targeted.

Version 1about 2 months ago

What changed: Added Definium Therapeutics as a new industry participant supporting the White House Executive Order.

President Donald Trump signed an executive order to accelerate approvals and expand access to psychedelic therapies, directing the FDA to prioritize reviews for 'breakthrough' treatments. The directive sparked a broad wave of buying across the sector, with Atai Life Sciences surging 28.1%, while Biomind Labs (BMND) announced its support for the order, noting its alignment with their mission to develop next-generation neuropsychiatric medicines. The order covers substances including psilocybin and MDMA, backed by at least $50 million in federal funding, positioning players like Compass Pathways and Numinus Wellness to benefit. While these companies remain in the clinical stage, analysts at RBC noted that federal action could significantly shorten the path to commercialization. This strategic move to address the mental health crisis has catalyzed significant market momentum, with Biomind Labs now identified as an additional entity directly impacted by the shift in U.S. policy.